According to preclinical research published in Cell, researchers with City of Hope discovered that a type of human immune cells known to be important for allergy and other immune responses—human type 2 innate lymphoid cells, or ILC2s—can also attack cancer.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
